Galapagos NV (GLPG) Stock Analysis
Healthcare · Biotechnology
Hold if already holding. Not a fresh buy at $27.73, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Below 200-day MA.
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus;... Read more
Hold if already holding. Not a fresh buy at $27.73, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Below 200-day MA. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Score 6.5/10, moderate confidence.
Passes 7/9 gates (positive momentum, clean insider activity, no SEC red flags, news events none recent, earnings proximity 83d clear, semi cycle peak clear, materials cycle peak clear). Fails on favorable risk/reward ratio. Suitability: aggressive.
Recent Developments — Galapagos NV
Latest news
- Galapagos NV, Gilead Sciences strike deal tied to Ouro Medicines acquisition - MSN — MSN positive
- Galapagos Shareholders Approve Name Change to Lakefront Biotherapeutics and Broad Governance Overhaul - TipRanks — TipRanks neutral
- Galapagos (NASDAQ: GLPG) investors approve name change and 10% buyback powers - Stock Titan — Stock Titan positive
- Galapagos (GLPG) Expected to Announce Quarterly Earnings on Wednesday - MarketBeat — MarketBeat neutral
- Galapagos NV (NASDAQ:GLPG) Given Average Recommendation of "Hold" by Analysts - MarketBeat — MarketBeat neutral
Generated 2026-05-20T21:06:21Z.
Thesis
Key Metrics
Quality Signals
Options Flow
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results. Full disclaimer
Rating Breakdown
1 ceiling hit
Price Targets
Position Sizing
Risk Alerts
Earnings
Verdict History
Frequently Asked Questions
Hold if already holding. Not a fresh buy at $27.73, but acceptable to hold if already in. Reasons: Analyst target reached - limited upside remaining; Below 200-day MA. Chart setup: No recognized chart pattern (not a breakout, bounce, continuation, recovery, falling knife, or range) — technicals mixed. Maintain position. Not compelling to add more. Target $28.85 (+4.0%), stop $26.51 (−4.6%), A.R:R -3.0:1. Score 6.5/10, moderate confidence.
Take-profit target: $28.85 (+4.0% upside). Target $28.85 (+4.0%), stop $26.51 (−4.6%), A.R:R -3.0:1. Stop-loss: $26.51.
Analyst target reached - limited upside remaining; Below 200-day MA; Value-trap signals (2/5): Revenue declining (-91.4% YoY), Margin compression (op margin -982.9%).
Galapagos NV trades at a P/E of 3.2 (forward -20.3). TrendMatrix value score: 9.6/10. Verdict: Hold.
18 analysts cover GLPG with a consensus score of 2.6/5. Average price target: $28.
What does Galapagos NV do?Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United...
Galapagos NV, a biotechnology company, develops medicines focusing on oncology and immunology primarily in the United States and Europe. The company's pipeline products comprise GLPG3667 that is in phase 2 clinical trial in dermatomyositis and systemic lupus erythematosus; GLPG5101, a CD19 CAR-T product candidate manufactured at point-of-care, currently in Phase1/2 trial in relapsed/refractory non-hodgkin lymphoma; and GLPG5301, a BCMA CAR-T product candidate manufactured at point-of-care, currently in phase 1/2 in relapsed/refractory multiple myeloma. The company has collaboration agreements with Gilead Sciences, Inc. The company was incorporated in 1999 and is headquartered in Mechelen, Belgium.